Download PDF

1. Company Snapshot

1.a. Company Description

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally.The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries.Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2.


The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies.Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.

Show Full description

1.b. Last Insights on PHN

Pharmanutra S.p.A.'s recent performance has been positively driven by its solid fundamentals and growth potential. The company's strong insider ownership suggests confidence from those closest to the business, aligning well with the current market optimism. A favorable European market environment, characterized by steady economic growth and a supportive monetary policy, has also contributed to the company's prospects. Additionally, Pharmanutra's position as a smaller, less prominent company may offer unique growth opportunities, making it an attractive investment target in the current robust market sentiment.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Undiscovered Gems in Europe for February 2026

Feb -10

Source:

Card image cap

European Growth Stocks With Strong Insider Ownership In January 2026

Jan -26

Source:

Card image cap

European Undiscovered Gems to Explore in January 2026

Jan -08

Source:

Card image cap

European Growth Stocks Insiders Are Banking On

Dec -26

Source:

Card image cap

European Growth Companies With High Insider Ownership To Watch

Nov -27

Source:

Card image cap

Avio And 2 Other Undiscovered Gems In Europe With Strong Potential

Nov -12

Source:

Card image cap

3 European Growth Stocks With Strong Insider Ownership

Oct -29

Source:

Card image cap

European Hidden Treasures To Watch This October 2025

Oct -03

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.68%)

6. Segments

Direct

Expected Growth: 10%

Pharmanutra S.p.A.'s 10% growth driven by increasing demand for nutraceuticals, expanding distribution channels, and strategic partnerships. Rising health awareness, aging population, and growing preference for natural remedies also contribute to growth. Additionally, investments in R&D and innovative products, such as SiderAL, support revenue expansion.

Indirect

Expected Growth: 12%

Pharmanutra S.p.A.'s 12% growth is driven by increasing demand for nutraceuticals, expansion into new markets, and strategic partnerships. The company's focus on R&D has led to innovative products, enhancing its competitive edge. Additionally, growing health awareness and an aging population have contributed to the rising demand for dietary supplements, further fueling growth.

Akern

Expected Growth: 11%

Akern from Pharmanutra S.p.A. growth driven by increasing demand for natural ingredients, expanding distribution channels, and strategic partnerships. Strong R&D investments in innovative products, such as SuPlextm, and growing online presence contribute to 11% growth.

7. Detailed Products

Selenium-Se

A dietary supplement containing selenium, an essential mineral that acts as an antioxidant in the body, protecting cells from damage caused by free radicals.

Myo-Inositol

A dietary supplement containing myo-inositol, a naturally occurring molecule involved in insulin signaling and glucose metabolism.

Melatonin

A dietary supplement containing melatonin, a hormone that regulates sleep-wake cycles.

Omega-3

A dietary supplement containing omega-3 fatty acids, essential for heart health and brain function.

Probiotics

A dietary supplement containing live microorganisms that promote gut health and immune system function.

Coenzyme Q10 (CoQ10)

A dietary supplement containing CoQ10, an antioxidant that generates energy in cells.

8. Pharmanutra S.p.A.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Pharmanutra S.p.A. is medium due to the presence of alternative products in the market, but the company's strong brand reputation and customer loyalty mitigate this threat.

Bargaining Power Of Customers

The bargaining power of customers is low for Pharmanutra S.p.A. due to the company's strong distribution network and customer relationships, which reduce the customers' ability to negotiate prices.

Bargaining Power Of Suppliers

The bargaining power of suppliers is medium for Pharmanutra S.p.A. due to the presence of multiple suppliers in the market, but the company's large scale of operations and strong relationships with suppliers mitigate this threat.

Threat Of New Entrants

The threat of new entrants is low for Pharmanutra S.p.A. due to the high barriers to entry in the pharmaceutical industry, including regulatory hurdles and high capital requirements.

Intensity Of Rivalry

The intensity of rivalry is high for Pharmanutra S.p.A. due to the presence of several established players in the market, leading to intense competition and pricing pressure.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 32.98%
Debt Cost 5.11%
Equity Weight 67.02%
Equity Cost 5.38%
WACC 5.29%
Leverage 49.21%

11. Quality Control: Pharmanutra S.p.A. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
PharmaSGP Holding

A-Score: 5.5/10

Value: 3.8

Growth: 6.6

Quality: 9.1

Yield: 2.5

Momentum: 3.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Reig Jofre

A-Score: 5.2/10

Value: 5.7

Growth: 7.9

Quality: 4.6

Yield: 1.9

Momentum: 4.0

Volatility: 7.0

1-Year Total Return ->

View Full Report
Stock-Card
Pharmanutra

A-Score: 4.2/10

Value: 1.3

Growth: 6.6

Quality: 8.2

Yield: 3.1

Momentum: 2.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
InterCure

A-Score: 3.1/10

Value: 7.4

Growth: 2.3

Quality: 2.7

Yield: 0.0

Momentum: 5.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Benchmark

A-Score: 2.8/10

Value: 6.4

Growth: 2.3

Quality: 5.2

Yield: 0.0

Momentum: 0.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
PolyPeptide

A-Score: 2.2/10

Value: 3.4

Growth: 4.0

Quality: 2.7

Yield: 0.0

Momentum: 2.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

65.95$

Current Price

65.95$

Potential

-0.00%

Expected Cash-Flows